8月20日，昭衍新药盘中上涨5.36%，报26.74港元，成交额1.66亿港元。该股前一交易日大跌6.39%，今日CXO板块集体走强，金斯瑞生物科技涨16.96%、药明生物涨6.05%、药明康德涨4.75%，板块联动带动个股反弹。
基本面上，公司截至一季度末在手订单31亿元，低价订单正有序出清，非人灵长类实验动物价格回升。公司将于8月28日召开董事会审议中期业绩，此前业绩预告显示上半年归母净利润预增884.9%至1377.4%，市场对业绩公布存在博弈预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.